ArticleProceedings of the National Academy of Sciences of the United States of America1993
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 111 citations in OpenAlex.
- Potential for anti‑angiogenic therapy targeting the receptor for advanced glycation end products/VEGF axis in ulcerative colitis (Review).Molecular medicine reports · 2026Review
- The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.Health science reports · 2022Review
- Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.Mucosal immunology · 2016Review
- S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
- The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.Handbook of clinical neurology · 2014Review
- Natural killer cells and their receptors in multiple sclerosis.Brain : a journal of neurology · 2013Review
- S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.Mediators of inflammation · 2013Review
- Quinoline: A versatile heterocyclic.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2013Article
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).British journal of pharmacology · 2011Review
- The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.Expert opinion on investigational drugs · 2010Review
- Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.PLoS biology · 2009Article
- Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model.International journal of biological sciences · 2008Article
- Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.Clinical and experimental immunology · 2004Article
- Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex.Inflammopharmacology · 2003Article
- Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis.Immunology · 1999Article
- Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).Cancer metastasis reviews · 1996Review
- Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.British journal of cancer · 1995Article
- Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.Diabetologia · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linomide is a synthetic immunomodulator that enhances natural killer cell activity and significantly activates several lymphocytic cell subpopulations in both experimental animals and humans. In this study we examined the effect of linomide (80 mg per kg per day in drinking water) on mice with chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE), a T-cell-mediated organ-specific autoimmune disease that resembles human multiple sclerosis. None of the mice (n = 17) that were treated with linomide from day 7 after disease induction developed any clinical or histopathological signs of CR-EAE, as compared to 19 of 20 untreated controls that were severely paralyzed and had extensive demyelinating lesions in the central nervous system. Linomide-treated animals were also resistant to an induced attack by a booster injection with a murine spinal cord homogenate. When administered to mice exhibiting severe clinical signs of paralysis, linomide inhibited both spontaneous and induced relapses. Linomide treatment protected mice from passively induced CR-EAE as well, when given from the day of injection with myelin-basic-protein-specific lymphocytes. Lymphocytes obtained from linomide-treated mice had a reduced in vitro proliferative response to the myelin basic protein and to the tuberculin purified protein derivative, whereas the mitogenic response to concanavalin A was not affected. Natural killer cell and lymphokine-activated killer cell activities were enhanced. These results suggest that linomide regulates autoimmunity in the absence of systemic immunosuppression. Since linomide is very well tolerated in experimental animals and humans, it might be used in the treatment of multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.